BioXcel Therapeutics Inc
$ 1.20
4.35%
20 Apr - close price
- Market Cap 31,135,800 USD
- Current Price $ 1.20
- High / Low $ 1.21 / 1.12
- Stock P/E N/A
- Book Value -4.28
- EPS -5.73
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.76 %
- ROE -17.67 %
- 52 Week High 8.08
- 52 Week Low 1.01
About
BioXcel Therapeutics, Inc., a clinical-phase biopharmaceutical company, focuses on the development of artificial intelligence-based drugs in the fields of neuroscience and immuno-oncology in the United States. The company is headquartered in New Haven, Connecticut.
Analyst Target Price
$14.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-27 | 2025-11-12 | 2025-08-12 | 2025-05-07 | 2025-03-10 | 2024-11-12 | 2024-08-06 | 2024-05-09 | 2024-03-12 | 2023-11-14 | 2023-08-14 | 2023-05-08 |
| Reported EPS | -1.0276 | -2.18 | -2.45 | -1.5 | -3.5627 | -0.32 | -0.21 | -0.87 | -0.76 | -1.72 | -1.83 | -1.84 |
| Estimated EPS | -0.635 | -0.09 | -0.13 | -3.04 | -5.1433 | -0.54 | -0.71 | -0.7 | -0.91 | -1.3 | -1.75 | -1.62 |
| Surprise | -0.3926 | -2.09 | -2.32 | 1.54 | 1.5806 | 0.22 | 0.5 | -0.17 | 0.15 | -0.42 | -0.08 | -0.22 |
| Surprise Percentage | -61.8268% | -2322.2222% | -1784.6154% | 50.6579% | 30.7312% | 40.7407% | 70.4225% | -24.2857% | 16.4835% | -32.3077% | -4.5714% | -13.5802% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.59 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BTAI
2026-04-19 03:09:31
BioXcel Therapeutics will host a virtual event on April 23, 2026, to discuss the commercial launch plan for IGALMI®, their treatment for acute agitation in bipolar disorders and schizophrenia, specifically for at-home use. This event precedes the November 14 PDUFA target action date and will detail the company's strategy based on a market assessment identifying up to 86 million addressable annual episodes of acute agitation in the at-home setting. The discussion will include key elements of the commercial plan and the substantial market opportunity for IGALMI.
2026-04-18 15:10:32
BioXcel Therapeutics (NASDAQ:BTAI) has issued warrants to its lenders for up to 1,353,729 shares of common stock as part of an amendment to its credit agreement. This move comes as the company's stock trades at $1.15, marking a 28% year-to-date decline. The warrants have an exercise price of $0.01 per share and will expire in seven years, while the company also continues to advance its BXCL501 and IGALMI programs.
2026-04-17 22:10:32
BioXcel Therapeutics has issued warrants to lenders to purchase up to 1,353,729 shares of its common stock as part of an amendment to its credit agreement. The warrants have an exercise price of $0.01 per share and a seven-year expiration. This move comes as the company continues to advance its pipeline, including a Phase 2a trial for BXCL501 and FDA acceptance of its supplemental New Drug Application for IGALMI.
2026-04-17 22:10:32
BioXcel Therapeutics (BTAI) issued warrants to its lenders as part of an amendment to its 2022 credit agreement, allowing them to purchase 1,353,729 common shares at a price of $0.01 per share. This move aims to align lender interests with company equity and involves a private placement structure for registration of these shares. Despite a "Buy" analyst rating with a $5.00 price target, TipRanks' AI Analyst "Spark" rates BTAI as Neutral due to weak financial performance and bearish technicals, tempered by potential upside from corporate events.
2026-04-17 21:10:31
BioXcel Therapeutics (NASDAQ: BTAI) has granted 1,353,729 warrants to lenders, exercisable at a low price of $0.01 per share. This action follows the Ninth Amendment to its Credit Agreement and Guaranty. The warrants, issued in a private transaction, will expire on the seventh anniversary of their issuance, and the company has also agreed to register the underlying shares.
2026-04-17 15:09:16
BioXcel Therapeutics will host a virtual event on April 23, 2026, to discuss the commercial launch plan for IGALMI® for acute agitation in the at-home setting, ahead of its November 14 PDUFA target action date. The event will detail insights from a recent market assessment identifying up to 86 million addressable annual episodes of acute agitation in the US. Mark Pavao, Interim Chief Commercial Officer, will outline the plan, and the event will be moderated by Michael King from Rodman & Renshaw.
